Physician profile
Michael L Levy
NPI 1164593927
$974.01
in general payments reported to CMS, 2019-2025
12 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $42.44 · 2022: $241 · 2023: $296 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Longeviti Neuro Solutions INC | $426.42 | 2023-2025 | Clearfit |
| Jazz Pharmaceuticals INC. | $160.87 | 2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2025 | |
| Lemaitre Vascular, INC. | $88.45 | 2019-2025 | Anastoclip Gc 8cm (Medium) |
| Alexion Pharmaceuticals, INC. | $30.00 | 2022 | |
| Brainlab, INC. | $29.51 | 2022 | |
| Cranial Technologies, INC | $29.29 | 2021 | |
| Aesculap, INC. | $21.94 | 2019 | |
| Baxter Healthcare | $20.78 | 2022 | |
| Abbott Laboratories | $14.46 | 2025 | Freestyle Libre |
| Axogen | $14.14 | 2019 | |
| Nx Development Corp. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.